Stoke Therapeutics Files 8-K Report

TL;DR

Stoke Therapeutics filed an 8-K on Dec 4th, check for updates.

AI Summary

On December 4, 2024, Stoke Therapeutics, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 45 Wiggins Ave, Bedford, Massachusetts.

Why It Matters

This 8-K filing provides important updates and disclosures from Stoke Therapeutics, Inc. to investors and the public.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain significant negative news.

Key Players & Entities

• Stoke Therapeutics, Inc. (company) — Registrant
• December 4, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 45 Wiggins Ave, Bedford, Massachusetts (location) — Address of Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Glo

Filing Documents

• d916273d8k.htm (8-K) — 35KB
• d916273dex991.htm (EX-99.1) — 15KB
• d916273dex992.htm (EX-99.2) — 28KB
• g916273g1206225109324.jpg (GRAPHIC) — 21KB
• g916273g1206225109624.jpg (GRAPHIC) — 20KB
• g916273g1206225335269.jpg (GRAPHIC) — 3KB
• 0001193125-24-272559.txt ( ) — 278KB
• stok-20241204.xsd (EX-101.SCH) — 3KB
• stok-20241204_lab.xml (EX-101.LAB) — 18KB
• stok-20241204_pre.xml (EX-101.PRE) — 11KB
• d916273d8k_htm.xml (XML) — 4KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated December 4, 2024 99.2 Press Release dated December 6, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to: the advantages that may be achieved by TANGO; the ability of zorevunersen (STK-001) to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in behavior or cognition at the indicated dosing levels or at all; the timing and expected progress of clinical trials, data readouts, regulatory decisions and other presentations for zorevunersen; the potential for zorevunersen to be the first disease-modifying therapy for Dravet syndrome; the timing of regulatory interactions or the outcomes thereof; the Company's expectations, plans, aspirations and goals, including those related to the potential of zorevunersen. Statements including words such as "anticipate," "believe," "hope," "plan," "will," "continue," "expect," "ongoing," or "potential" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause the Company's results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the Company's ability to advance, obtain regulatory approval of, and ultimately commercialize its product candidates, including zorevunersen; the timing of data readouts and interim and final results of preclinical and clinical trials; preclinical and clinical data are voluminous and detailed, and regulatory authorities may interpret or weigh the importance of data differently and reach different conclusions than us or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; receiving Breakthrough Therapy Designation m

View Full Filing

View this 8-K filing on SEC EDGAR